Stay updated with breaking news from Expanded Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta VariantOpaganib demonstrated strong inhibition of COVID-19 Delta variant in a human bronchial epithelial cells model, adding
Investor interest is pushing psychedelics-based therapy mainstream and it’s now time to figure out the tricky regulatory issues that have held these therapies back, as the leading developer moves towards seeking approval in 2023.
In addition to the Company’s eight ongoing clinical trials, HAVs have been used in 13 expanded access cases for emergent life- and limb-saving vascular...
Read the latest Ivermectin headlines - updated 24/7/365. We link to the best sources from around the world. Get the latest on Ivermectin...
GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update ATUs in France in Europe in H1 2022 Successful refinancing in Q1 2021 secures mid-2023 runway Multiple regulatory and clinical milestones expected in Q4 2021 Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its interim financial results for the first half of 20...